Skip to main content

3 Result(s)

within K M Laumann Remove this filter Hematology Remove this filter

and

  1. No Access

    Article

    Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial

    Despite therapeutic advances, multiple myeloma remains incurable, with limited options for patients with refractory disease. We conducted a large, multi-cohort clinical trial testing various doses and treatmen...

    S Ailawadhi, J R Mikhael, B R LaPlant, K M Laumann, S Kumar, V Roy, D Dingli… in Leukemia (2018)

  2. No Access

    Article

    A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma

    Patients with asymptomatic (smoldering) multiple myeloma (AMM) have a high risk of transformation to active multiple myeloma (MM). Bisphosphonates such as zoledronic acid (ZLD) reduce skeletal events in MM and...

    T E Witzig, K M Laumann, M Q Lacy, S R Hayman, A Dispenzieri, S Kumar… in Leukemia (2013)

  3. No Access

    Article

    Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma

    P Kapoor, S Kumar, S J Mandrekar, K M Laumann, A Dispenzieri, M Q Lacy… in Leukemia (2011)